

EYLEA HD[®] (aflibercept) Injection Payer Coverage as of 04/15/2026

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

EYLEA HD, EYLEA, and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

Copyright © 2025, Regeneron Pharmaceuticals, Inc. All rights reserved. 11/2025 US.EHD.25.07.0315

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA[®] (aflibercept) Injection.



EYLEA HD[®]
(aflibercept) Injection 8 mg

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA

INDICATIONS

EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) Injection 2 mg are indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Macular Edema following Retinal Vein Occlusion (RVO).

IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA

CONTRAINDICATIONS

- EYLEA HD and EYLEA are contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or any of the excipients in EYLEA HD or EYLEA.

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering EYLEA HD or EYLEA. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
- Acute increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including with EYLEA HD and EYLEA. Sustained increases in IOP have also been reported after repeated intravitreal dosing with VEGF inhibitors. IOP and the perfusion of the optic nerve head should be monitored and managed appropriately.

2 Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA

WARNINGS AND PRECAUTIONS (cont'd)

- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD and EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
 - EYLEA HD: The incidence of reported ATEs in the Wet AMD study from baseline through week 48 was 0.4% (3 out of 673) in the combined group of patients treated with EYLEA HD compared with 1.5% (5 out of 336) in patients treated with EYLEA 2 mg. The incidence in the DME study from baseline to week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg. The incidence in the RVO study from baseline to week 36 was 0.5% (3 out of 591) in the combined group of patients treated with EYLEA HD compared with 1.7% (5 out of 301) in patients treated with EYLEA 2 mg.
 - EYLEA: The incidence of reported ATEs in Wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.

3 Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA[®] (aflibercept) Injection.



INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA

ADVERSE REACTIONS

- **EYLEA HD:** The most common adverse reactions ($\geq 3\%$) reported in patients receiving EYLEA HD were cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment, and vitreous floaters.
- **EYLEA:** Serious adverse reactions related to the injection procedure have occurred in $<0.1\%$ of intravitreal injections with EYLEA including endophthalmitis and retinal detachment. The most common adverse reactions ($\geq 5\%$) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
- Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD or EYLEA and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

EYLEA HD Payer Coverage as of 04/15/2026

MACs

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
Palmetto GBA – Jurisdiction JJ	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Palmetto GBA – Jurisdiction JM	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Novitas Solutions – Jurisdiction JH	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Novitas Solutions – Jurisdiction JL	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Nat'l Gov't Serv. (NGS) – Jurisdiction JK	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Nat'l Gov't Serv. (NGS) – Jurisdiction J6	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Wisc. Phys Serv. (WPS) – Jurisdiction J5	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Wisc. Phys Serv. (WPS) – Jurisdiction J8	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Celerian Group Co. (CGS) – Jurisdiction J15	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
First Coast Service Options (FCSO) – Jurisdiction FL	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Noridian Healthcare Solutions – Jurisdiction JE	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A
Noridian Healthcare Solutions – Jurisdiction JF	Medicare	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	12/12/2024	N/A

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MAC = Medicare Administrative Contractor; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD[®]
(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

National Payers

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
UnitedHealthcare	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	04/01/2026	Link
	Medicare Advantage	DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
Wet AMD		Single agent step through 3 consecutive monthly bevacizumab injections			
Humana	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	03/01/2026	Link
Anthem BCBS (Elevance Health)	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	03/26/2026	Link
Aetna	Medicare Advantage	Wet AMD, MEfRVO	Single agent step through bevacizumab	04/01/2026	Link
		DME, DR	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
	Commercial	Wet AMD, DME, DR, MEfRVO	Double agent step through bevacizumab and ranibizumab-nuna	03/16/2026	Link
BCBS Federal Employee Program	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/06/2026	Link
Cigna	Commercial	Wet AMD, DR, MEfRVO	Single agent step through bevacizumab	02/01/2026	Link
		DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
Department of Veterans Affairs (VA)	Veterans Affairs	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	04/02/2026	Link
Department of Defense (DoD)	Government	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	11/01/2023	N/A

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD®

(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
Aultcare Health	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	N/A
BCBS of Alabama	Commercial	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	01/01/2026	Link
BCBS of Arkansas	Commercial	Wet AMD, DME, DR	See policy	01/01/2026	Link
Blue Shield of California	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	03/01/2026	Link
BCBS of Illinois (HCSC)	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	05/01/2025	Link
	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
BCBS of Kansas City	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	N/A
BCBS of Kansas	Medicare Advantage		First-line access, no step edit	08/02/2024	N/A
	Commercial	Wet AMD, DME, DR	Double agent step through bevacizumab and ranibizumab or ranibizumab biosimilar	11/04/2025	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

[†]Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD[®]
(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically) (cont'd)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
BCBS of Massachusetts	Commercial	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	03/15/2026	Link
	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	01/01/2026	Link
BCBS of Michigan	Commercial and Medicare Advantage	Wet AMD, DR, MEfRVO	Single agent step through bevacizumab	02/12/2026	Link
		DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
BCBS of Minnesota	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	01/06/2026	Link
BCBS of Montana (HCSC)	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	05/01/2025	Link
BCBS of Nebraska	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	11/06/2024	Link
BCBS of New Mexico (HCSC)	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	05/01/2025	Link
BCBS of North Carolina	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	03/01/2026	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD®

(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically) (cont'd)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
BCBS of North Dakota	Commercial	Wet AMD, DR, DME, MEfRVO	Single agent step through bevacizumab	01/06/2026	Link
BCBS of Oklahoma (HCSC)	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	05/01/2025	Link
BCBS of Rhode Island	Commercial	Wet AMD, DME, DR	See policy	07/01/2025	Link
BCBS of South Carolina	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Double agent step through ranibizumab, faricimab and/or ranibizumab biosimilar	02/01/2026	Link
BCBS of Tennessee	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	02/01/2026	Link
BCBS of Texas (HCSC)	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	05/01/2025	Link
Capital Blue Cross	Commercial	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	01/06/2026	Link
CareFirst BCBS	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	03/16/2026	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD[®]
(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically) (cont'd)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
Centene	Commercial and Medicare Advantage	Wet AMD, DR, MEfRVO	Single agent step through bevacizumab	03/01/2026	Link
		DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
Corewell Health (Priority Health)	Commercial	Wet AMD, DR, MEfRVO	Single agent step through 3 consecutive monthly bevacizumab injections	04/15/2026	Link
		DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit		
EmblemHealth	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/06/2026	Link
Excellus (BCBS)	Commercial and Medicare Advantage	Wet AMD, MEfRVO	Single agent step through 3 bevacizumab injections	04/01/2026	Link
		DME, DR	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
Florida Blue	Commercial	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	02/15/2026	Link
	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	03/01/2026	Link
Geisinger	Commercial and Medicare	Wet AMD, DME, DR	See policy	02/01/2026	Link
Hawaii Medical Service Association (HMSA)	Commercial and Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	04/07/2026	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

**Please see Important Safety Information throughout and full Prescribing Information
10 for EYLEA HD and EYLEA® (aflibercept) Injection.**



EYLEA HD[®]
(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically) (cont'd)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
HealthPartners	Commercial	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	01/01/2026	Link
	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	09/01/2025	Link
Highmark BCBS	Commercial and Medicare Advantage	DME, DR, MEfRVO	First-line access, no step edit	03/02/2026	Link
		Wet AMD	Single agent step through 3 consecutive monthly bevacizumab injections		
Horizon BCBS of NJ	Commercial, Medicare Advantage, and Managed Medicaid	Wet AMD, DME, DR, MEfRVO	Double agent step through bevacizumab and EYLEA	11/04/2025	Link
Independence Blue Cross	Commercial	Wet AMD, DME, DR, MEfRVO	Double agent step through bevacizumab and ranibizumab	01/01/2026	Link
	Medicare Advantage				Link
Independent Health	Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through bevacizumab	12/01/2023	Link
Louisiana Blue	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	04/15/2026	N/A
Mass General Brigham Health	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab, ranibizumab, or EYLEA	08/01/2025	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information

11 for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD®

(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically) (cont'd)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
Medica	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Single agent step through 3 consecutive monthly bevacizumab injections	09/05/2024	Link
Medical Mutual of Ohio	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Double agent step through bevacizumab and EYLEA	03/19/2026	Link
Moda Health	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Double agent step through bevacizumab and EYLEA	03/06/2026	Link
Oscar	Commercial	Wet AMD, DME, DR, MEfRVO	See policy	04/15/2026	Link
Point32Health (Tufts and Harvard Pilgrim)	Commercial	Wet AMD, DME, DR, MEfRVO	Double agent step through 3 consecutive monthly bevacizumab injections and 1 EYLEA injection or ranibizumab	02/01/2026	Link
	Medicare Advantage			04/01/2026	Link
Premera Blue Cross	Commercial	Wet AMD, DME, DR, MEfRVO	See policy	02/01/2026	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

**Please see Important Safety Information throughout and full Prescribing Information
12 for EYLEA HD and EYLEA® (aflibercept) Injection.**



EYLEA HD[®]
(aflibercept) Injection 8 mg

EYLEA HD Payer Coverage as of 04/15/2026

Regional Payers (listed alphabetically) (cont'd)

Health Plan*	Channel	Indication(s)	Status [†]	Effective Date	Policy Link
Providence Health Plan (OR, WA, and CA)	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	See policy	01/01/2026	N/A
Regence	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through bevacizumab and ranibizumab or ranibizumab biosimilar	04/01/2026	Link
Sentara Health Plan	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	Double agent step through bevacizumab and EYLEA	02/16/2026	Link
UCare Minnesota	Medicare Advantage	Wet AMD, DR	Single agent step through bevacizumab	01/06/2025	Link
		DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
UPMC Health	Commercial and Medicare Advantage	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	03/01/2026	Link
Wellmark BCBS of IA/SD	Commercial	Wet AMD, DME, DR, MEfRVO	First-line access, no step edit	01/01/2026	Link
	Medicare Advantage	Wet AMD, DR, MEfRVO	Single agent step through bevacizumab	01/01/2026	Link
	DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better			

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; MEfRVO = macular edema following retinal vein occlusion.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2026.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a statement of benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information

13 for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD®

(aflibercept) Injection 8 mg